Outlook Therapeutics, Inc. — Form 8-K
Filed July 16, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Outlook Therapeutics amended its Restated Certificate of Incorporation effective July 16, 2026, to authorize 600 million common shares (par value $0.01) and 10 million preferred shares (par value $0.01), totaling 610 million authorized shares. The amendment was approved by stockholders per Delaware General Corporation Law Section 242. No specific details on prior authorization levels or reason for adjustment are disclosed in this filing.
Why this rating
Routine capital structure amendment. No dilution event, financing, or operational impact disclosed; standard corporate governance housekeeping relative to $26.9M market cap.
See more from July 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.